Upexi (UPXI) Competitors

Upexi has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Keros Therapeutics has higher revenue and earnings than Upexi. Keros Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 9.0% of Upexi shares are owned by insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Keros Therapeutics has a net margin of -256.60% compared to Upexi's net margin of -874.00%. Keros Therapeutics' return on equity of -17.04% beat Upexi's return on equity.

In the previous week, Keros Therapeutics had 2 more articles in the media than Upexi. MarketBeat recorded 2 mentions for Keros Therapeutics and 0 mentions for Upexi. Upexi's average media sentiment score of 1.87 beat Keros Therapeutics' score of 0.97 indicating that Upexi is being referred to more favorably in the media.

Upexi currently has a consensus price target of $8.10, suggesting a potential upside of 906.71%. Keros Therapeutics has a consensus price target of $20.40, suggesting a potential upside of 91.73%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than Keros Therapeutics.

Voyager Therapeutics has a net margin of -319.61% compared to Upexi's net margin of -874.00%. Voyager Therapeutics' return on equity of -55.97% beat Upexi's return on equity.

In the previous week, Voyager Therapeutics had 3 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Voyager Therapeutics and 0 mentions for Upexi. Upexi's average media sentiment score of 1.87 beat Voyager Therapeutics' score of 0.78 indicating that Upexi is being referred to more favorably in the media.

Upexi has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Upexi has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

5.7% of Upexi shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 9.0% of Upexi shares are owned by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Upexi presently has a consensus target price of $8.10, suggesting a potential upside of 906.71%. Voyager Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 420.50%. Given Upexi's higher possible upside, equities analysts plainly believe Upexi is more favorable than Voyager Therapeutics.

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 1 mentions for Karyopharm Therapeutics and 0 mentions for Upexi. Upexi's average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 1.61 indicating that Upexi is being referred to more favorably in the news media.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Upexi has lower revenue, but higher earnings than Karyopharm Therapeutics. Upexi is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Upexi has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market.

Karyopharm Therapeutics currently has a consensus price target of $17.17, indicating a potential upside of 80.51%. Upexi has a consensus price target of $8.10, indicating a potential upside of 906.71%. Given Upexi's higher probable upside, analysts plainly believe Upexi is more favorable than Karyopharm Therapeutics.

Karyopharm Therapeutics has a net margin of -129.02% compared to Upexi's net margin of -874.00%. Karyopharm Therapeutics' return on equity of 0.00% beat Upexi's return on equity.

Avidity Biosciences currently has a consensus target price of $67.60, indicating a potential upside of 456.38%. Upexi has a consensus target price of $8.10, indicating a potential upside of 906.71%. Given Upexi's stronger consensus rating and higher possible upside, analysts plainly believe Upexi is more favorable than Avidity Biosciences.

Upexi has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Avidity Biosciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Upexi has a beta of -0.29, indicating that its stock price is 129% less volatile than the broader market.

Upexi has a net margin of -874.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Upexi's return on equity.

In the previous week, Avidity Biosciences had 2 more articles in the media than Upexi. MarketBeat recorded 2 mentions for Avidity Biosciences and 0 mentions for Upexi. Upexi's average media sentiment score of 1.87 beat Avidity Biosciences' score of 1.00 indicating that Upexi is being referred to more favorably in the news media.

5.7% of Upexi shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.